Bivalirudin anticoagulation for cardiopulmonary bypass: an unusual case

Tex Heart Inst J. 2007;34(1):115-8.

Abstract

The standard agent used for systemic anticoagulation during cardiopulmonary bypass is heparin. Alternative methods of anticoagulation are required for patients with heparin hypersensitivity. We present the case of a patient with heparin hypersensitivity who was anticoagulated with bivalirudin during cardiopulmonary bypass for coronary artery bypass grafting. This presented unusual challenges surrounding the monitoring of anticoagulation and the method of myocardial protection.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anticoagulants / therapeutic use*
  • Cardiopulmonary Bypass*
  • Combined Modality Therapy
  • Coronary Artery Bypass
  • Coronary Stenosis / complications
  • Coronary Stenosis / therapy
  • Drug Hypersensitivity / etiology
  • Heparin / adverse effects
  • Hirudins
  • Humans
  • Male
  • Myocardial Infarction / etiology
  • Myocardial Infarction / therapy
  • Peptide Fragments / therapeutic use*
  • Recombinant Proteins / therapeutic use
  • Ventricular Dysfunction, Left / etiology
  • Ventricular Dysfunction, Left / therapy
  • Ventricular Fibrillation / etiology
  • Ventricular Fibrillation / therapy

Substances

  • Anticoagulants
  • Hirudins
  • Peptide Fragments
  • Recombinant Proteins
  • Heparin
  • bivalirudin